J&J To Pay $400M Over Criminal Charge In Risperdal Case

By Dan Packel (November 7, 2013, 9:01 PM EST) -- A Pennsylvania federal judge on Thursday approved a $400 million criminal penalty against Johnson & Johnson unit Janssen Pharmaceuticals Inc., part of a larger $2.2 billion settlement announced Monday, after the company formally admitted to improperly encouraging doctors to use Risperdal to treat dementia.

U.S. District Judge Timothy Savage approved the sentence for one criminal misdemeanor charge of introducing a misbranded drug into interstate commerce, noting that the company's conduct had far greater consequences than those acknowledged in the plea.

"The company compromised the integrity of the delivery of medical services, which had a tendency to corrupt the decisions of physicians...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!